secwatch.observer — SEC 8-K summary
======================================

Issuer:     Equillium, Inc. (EQ)
CIK:        0001746466
Form:       8-K
Filed at:   2022-09-27T23:59:59+00:00
Accession:  0001193125-22-251807
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Equillium reports interim itolizumab data in LN: 50% CR at week 28, 67% >80% UPCR reduction
--------------------------------------------------------------------------------

- Baseline mean UPCR 5.8 g/g; 13 subjects enrolled, 11 reached week 12, 6 reached week 28/EOS.
- At week 28: 3/6 (50%) achieved complete response (UPCR <0.7 g/g); 2/6 (33%) partial response.
- 4/6 (67%) achieved >80% reduction in UPCR; average 60% reduction across all dosed subjects.
- No drug-related serious adverse events or treatment discontinuations; steroid tapered to <7.5 mg/day.
- Top-line Type B data expected mid-2023; pending Metacrine acquisition also noted in filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1746466/000119312522251807/0001193125-22-251807-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1746466/000119312522251807/d383524d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-251807

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer